India, Nov. 14 -- Lupin Limited has announced the U.S. launch of Risperidone for extended-release injectable suspension—available in 25 mg, 37.5 mg, and 50 mg single-dose vials—after receiving approval from the U.S. FDA. The product comes with 180-day Competitive Generic Therapy (CGT) exclusivity and marks the first commercial release from Lupin's proprietary long-acting injectable platform, PrecisionSphere™, developed by its subsidiary Nanomi B.V.
Nanomi's LAI platform uses PrecisionSphere™ technology to create uniform microspheres that enable controlled drug release from weeks to months, improved injectability with smaller needles, and consistent therapeutic concentrations. Lupin aims to expand the platform's reac...